Eli Lilly stock tumbles on Q3 miss; Zepbound sales fall short

Eli Lilly and Company, a leading global pharmaceutical company, experienced a significant decline in its stock value as it reported lower-than-expected sales and a miss on its Q3 earnings. The company's flagship drug, Zepbound, also fell short of projected sales figures, contributing to the overall disappointment. As a result, the stock price tumbled, causing concerns among investors and analysts. The company has since slashed its profit guidance for the year. Experts recommend seeking professional advice from Stocks Prognosis to navigate the forecasted movement of Eli Lilly's stock.